Lee Tim W R, Matthews David A, Blair G Eric
School of Biochemistry and Microbiology, University of Leeds, Leeds LS2 9JT, UK.
Biochem J. 2005 Apr 1;387(Pt 1):1-15. doi: 10.1042/BJ20041923.
Gene therapy holds promise for the treatment of a range of inherited diseases, such as cystic fibrosis. However, efficient delivery and expression of the therapeutic transgene at levels sufficient to result in phenotypic correction of cystic fibrosis pulmonary disease has proved elusive. There are many reasons for this lack of progress, both macroscopically in terms of airway defence mechanisms and at the molecular level with regard to effective cDNA delivery. This review of approaches to cystic fibrosis gene therapy covers these areas in detail and highlights recent progress in the field. For gene therapy to be effective in patients with cystic fibrosis, the cDNA encoding the cystic fibrosis transmembrane conductance regulator protein must be delivered effectively to the nucleus of the epithelial cells lining the bronchial tree within the lungs. Expression of the transgene must be maintained at adequate levels for the lifetime of the patient, either by repeat dosage of the vector or by targeting airway stem cells. Clinical trials of gene therapy for cystic fibrosis have demonstrated proof of principle, but gene expression has been limited to 30 days at best. Results suggest that viral vectors such as adenovirus and adeno-associated virus are unsuited to repeat dosing, as the immune response reduces the effectiveness of each subsequent dose. Nonviral approaches, such as cationic liposomes, appear more suited to repeat dosing, but have been less effective. Current work regarding non-viral gene delivery is now focused on understanding the mechanisms involved in cell entry, endosomal escape and nuclear import of the transgene. There is now increasing evidence to suggest that additional ligands that facilitate endosomal escape or contain a nuclear localization signal may enhance liposome-mediated gene delivery. Much progress in this area has been informed by advances in our understanding of the mechanisms by which viruses deliver their genomes to the nuclei of host cells.
基因治疗有望用于治疗一系列遗传性疾病,如囊性纤维化。然而,治疗性转基因的有效递送和表达,要达到足以实现囊性纤维化肺部疾病表型纠正的水平,却一直难以实现。造成这种进展不足的原因有很多,从宏观层面的气道防御机制来看,以及在分子层面的有效cDNA递送方面。这篇关于囊性纤维化基因治疗方法的综述详细涵盖了这些领域,并突出了该领域的最新进展。为使基因治疗对囊性纤维化患者有效,编码囊性纤维化跨膜传导调节蛋白的cDNA必须有效地递送至肺内支气管树内衬上皮细胞的细胞核。转基因的表达必须在患者的整个生命周期内维持在适当水平,要么通过重复给予载体,要么通过靶向气道干细胞来实现。囊性纤维化基因治疗的临床试验已证明了其原理,但基因表达最多只能持续30天。结果表明,腺病毒和腺相关病毒等病毒载体不适合重复给药,因为免疫反应会降低后续每次给药的效果。非病毒方法,如阳离子脂质体,似乎更适合重复给药,但效果较差。目前关于非病毒基因递送的工作现在集中在了解转基因进入细胞、从内体逃逸和核输入所涉及的机制。现在越来越多的证据表明,促进内体逃逸或含有核定位信号的额外配体可能会增强脂质体介导的基因递送。我们对病毒将其基因组递送至宿主细胞核的机制的理解取得了进展,这为该领域的许多进展提供了依据。